Jonathan Mosley Archive — Page 1 of 1

February 1, 2024

A biomarker for early Type 2 diabetes

Genetic analyses suggest that branched chain amino acids may be a sensitive biomarker of early or subclinical Type 2 diabetes and could be used to identify risk and implement preventive measures.

By Bill Snyder
October 31, 2023

Polygenic ‘scores’ may improve cancer screening

Accounting for genetic variability in biomarkers not associated with cancer risk could avoid unnecessary diagnostic procedures, Vanderbilt researchers found.

By Bill Snyder
Research by Mingjian Shi, PhD, left, Jonathan Mosley, MD, PhD, Kerry Schaffer, MD, MSCI, and colleagues found that polygenic risk score does not improve prediction of aggressive prostate cancer.
March 16, 2023

Study evaluates polygenic risk score for prostate cancer risk prediction

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.

By Leigh MacMillan
August 11, 2022

Genotype-specific blood counts

Vanderbilt researchers report genotype-specific reference ranges to improve interpretation of laboratory blood results in African Americans with a common gene variant that lowers white blood cell counts.

By Leigh MacMillan
June 16, 2022

BMI genetics influence heart function

Vanderbilt researchers have discovered that a genetic predisposition to elevated body mass index increases the risk of diastolic dysfunction — a cardiac condition that can lead to heart failure.

By Leigh MacMillan
From left, Dan Roden, MD, Ayesha Muhammad, Jonathan Mosley, MD, PhD, and Sara Van Driest, MD, PhD, found that a genome-wide approach can improve the prediction of drug responses.
July 22, 2021

For more precise drug treatments, ‘squeeze’ the genome: study finds

Large-scale studies will be required to identify the complexity of genetic variations that affect how patients respond to a given drug and whether they will have side effects, according to researchers at Vanderbilt University Medical Center.

By Bill Snyder